case report

Combination of factor V Leiden and MTHFR mutations in myocardial infarction

Najiba Fekih-Mrissa, a Dhouha Berredjeb-Benslama, a Abdeddayem Haggui, b Habib Haouala, b Nasreddine Gritlia

From the aLaboratory of Molecular Biology, Department of Hematology, and the bDepartment of Cardiology, Military Hospital, Tunis, Tunisia

Correspondence: Najiba Fekih-Mrissa  · Laboratory of Molecular Biology, Department of Hematology, Military Hospital, 1008 Mont Fleury, Tunis, Tunisia · T: +21622510488 · fnajiba@yahoo.fr

Ann Saudi Med 2013; 33(2): 192-193
DOI: 10.5144/0256-4947.2012.01.7.1520

Identifying patients who are at high risk of suffering myocardial infarction can be done by determining risk factors or by the adoption of molecular genetic testing for inherited thrombophilia. We report a case of myocardial infarction at a young age. The patient complained of dyspnea (stage III) and a burning pain of severe intensity that radiated to the left retrosternal side, but was not associated with palpitations or diaphoresis. A number of biochemical parameters were normal except for an elevated creatinine phosphokinase (CPK) level. Genetic testing revealed the subject to be heterozygous for both the factor V leiden and MTHFR C677T polymorphisms. The combination of these two mutations may be a high risk factor for myocardial infarction. Genetic screening for inherited thrombophilia in young patients, especially in the presence of a common risk factor, may be useful for primary thromboprophylaxis and in asymptomatic relatives of patients.

Myocardial infarction (MI) is an important clinical problem because of its large contribution to mortality. The most important and common risk factors for MI include hypertension, hypercholesterolemia or dyslipidemia, diabetes mellitus, and smoking. Some recent studies have also demonstrated the important relationship between prothrombotic genetic markers and MI.1 For example, several reports on the association between the factor V Leiden mutation and MI in young patients are available.2,3 Other studies, however, have cast doubt on the role of certain thrombotic genetic markers and MI. One such study found no strong evidence to support an association of the C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism and coronary heart disease in different populations.4 This report concerns the case of a young subject who had a heterozygous defect in the factor V Leiden gene as well as C677T MTHFR polymorphism. The combination of these mutations, along with his past smoking habit, is suspected to be the probable cause of his MI.

CASE
A previously healthy 48-year-old Tunisian male was admitted to our cardiology department with oppressive chest pain. The patient complained of dyspnea (stage III) and a burning retrosternal pain that was severe in intensity and radiated to the left side but was not associated with palpitations or diaphoresis. Currently a nonsmoker, he had been a 1-pack-per-day smoker. His blood pressure was 140/80 mm Hg and pulse rate was 80/min; other clinical parameters were stable. The patient had a positive family history of hypertension.

Biochemical studies, electrocardiogram, and echocardiography were performed. A coronary angiogram revealed completely normal coronary arteries. Platelet, fibrinogen, prothrombin, protein S, protein C, and antithrombin III levels were all found to be normal. Tests for antiphospholipid and anticardiolipin antibodies were negative. Cardiac enzymes were measured: the troponin level was normal (<0.01 ng/mL); however, the creatine phosphokinase was elevated to 253 IU/L (normal, 10-195 IU/L). A complete genotype analysis for inherited thrombophilia was carried out on total DNA extracted from blood. PCR was used with a commercial kit (ThromboType plus; Hain Lifescience, Nehren, Germany). The test for the prothrombin G20210A and MTHFR A1298C mu-
tations were negative, but the patient was found to be heterozygous for factor V Leiden and positive for C677T MTHFR mutation. MI was diagnosed and treatment was instituted. Anticoagulation therapy with aspirin, atenolol (Hypoten) and captopril (Lopril) was effective. The patient was followed up in the cardiology department and continued to do well at home 3 years after discharge.

**DISCUSSION**

The identification of patients who are at high risk of suffering MI can be done by assessing risk factors or by molecular genetic testing for inherited thrombophilia. This is of great importance, particularly for asymptomatic first-degree relatives of MI patients. Genetic disorders of coagulation proteins, in general, have important effects on thrombus formation, thrombolysis, or both. The most commonly encountered gene polymorphisms may increase the risk for ischemic heart disease. Specifically, the role of thrombophilia in the pathogenesis of MI has been intensely studied in recent years and is still debated. For example, the association between the homozygous 677TT MTHFR polymorphism and MI have been examined, but the results of studies demonstrated that the role of MTHFR in MI was not well established. Moreover, other studies have failed to establish a definitive role of certain inherited thrombophilias in MI. Recently, however, large-scale multigenic association studies have revealed that the C677T MTHFR polymorphism is a significant risk factor associated with the prevalence of MI. Similarly, while a retrospective study did not demonstrate an increased prevalence of the heterozygous factor V Leiden mutation in patients with MI, other studies have reported that the risk of suffering an MI was increased by 40% in heterozygote carriers of the factor V Leiden mutation. A synergistic effect between atherogenic risk factors and thrombogenic mutations in the pathogenesis of MI has also been suggested. In particular, the concomitant presence of smoking and factor V Leiden mutation was found to increase the risk of MI in young men. Therefore, in our patient, MI may have been a consequence of the synergism between inherited thrombophilia and cigarette smoking. Indeed, genetic testing for prothrombotic mutations might be important in selecting patient management, such as prophylactic anticoagulation therapy or institution of measures for avoidance of behavioral risk factors, such as smoking.

In conclusion, it is likely that the combination of factor V Leiden mutation and the C677T MTHFR polymorphism, in the presence of conventional risk factors, increased the risk of MI in our case. Genetic typing could prove useful in identifying subjects who require prophylactic treatment so as to avoid such cardiovascular events.

**Acknowledgment**

We would like to thank Dr. Christian Winchell for his help in correcting this manuscript.

**REFERENCES**

1. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2002;144:548-57.
2. Dörmaz Y, Kanadasi M, Tannverdi K, Demir M, Demirtaş M, Çaylı M, et al. Prothrombin 20210A and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004;45:505-12.
3. Hobikoglu GF, Akyüz U, Akyüz F, Özer O, Güney D, Narin A, et al. Factor V Leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 2004;59:594-7.
4. Lewis SJ, Ibrahim S, Davey Smith G. Meta-analysis of MTHFR 677C–NT polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and prevent potential of folate? BMJ 2005;331:1053.
5. Feng YJ, Draghi A, Limfert DR, Wu AH, Tsongalis GJ. Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. Arch Pathol Lab Med 1999;123:1230-5.
6. Inbal A, Freemark D, Modan B, Chetrit A, Matetzky S, Rosenbarg N, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999;93:2186-90.
7. Redondo M, Watzke HH, Stucki J, Sulzer I, Demmelts Biasiutti F, Binder BR, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G!A transition, and factor V Leiden in coronary artery disease: High factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:1020-5.
8. Yamada Y, Matsuo H, Sagawa T, Watanabe S, Kato K, Hibino T, et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost 2006;96:220-7.
9. McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, Plow EF, et al. GeneQuest Investigators. Large scale association analysis for identification of genes underlying premature coronary heart disease: Cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004;41:234-41.
10. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiller D, Luc G, et al. Myocardial infarction, Arg306 to Glu factor V mutation, and activated protein C resistance. Lancet 1995;345:321.
11. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-41.
12. Hobikoglu GF, Akyüz U, Akyüz F, Özer O, Güney D, Narin A, et al. Factor V Leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 2004;59:594-7.
13. Satıroğlu Ö, Vural M, Uyar I, Bostan M. Acute anterior myocardial infarction in a young male patient homozygous for the factor V Leiden mutation. Arch Turk Soc Cardiol 2010;38:194-7.
14. Federici C, Gianetti J, Andreassi MG. Genomic medicine and thrombotic risk: Who, when, how and why? Int J Cardiol 2006;106:3-9.